Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".

Affronti, Mary Lou; Herndon, James E; Patel, Mallika P

Affronti, Mary Lou; Herndon, James E; Patel, Mallika P.

Affiliation

Affronti ML; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, 047 Baker House, Trent Drive, DUMC Box 3624, Durham, NC, 27710, USA. mary.affronti@duke.edu.
Herndon JE; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA. mary.affronti@duke.edu.
Patel MP; Duke University School of Nursing, Duke University, Durham, NC, USA. mary.affronti@duke.edu.

Support Care Cancer ; 28(12): 5591-5592, 2020 12.

Article de En | MEDLINE | ID: mdl-32885313

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Gliome / Antinéoplasiques Type d'étude: Clinical_trials Limites: Humans Langue: En Journal: Support Care Cancer Sujet du journal: NEOPLASIAS / SERVICOS DE SAUDE Année: 2020 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google